Evaluate regulatory compliance, client concentration, lab partnerships, and true margin before closing on a DOT-authorized drug testing collection business.
Find Drug Testing Services Acquisition TargetsAcquiring a drug testing services business requires scrutiny beyond standard financials. Buyers must isolate collection revenue from pass-through lab charges, validate DOT and SAMHSA compliance history, and assess owner dependency across employer accounts before committing capital.
Separate true collection and MRO service revenue from pass-through lab charges to establish accurate gross margin and identify client concentration risks within the employer contract base.
Isolate collection fees, MRO review billings, and consortium management revenue from pass-through lab charges. Pass-through revenue inflates top-line without contributing meaningful margin.
Map revenue by employer account and industry segment. Flag any single client exceeding 20% of collections volume as a material churn risk requiring earnout or escrow protection.
Confirm whether employer agreements are multi-year contracts, month-to-month purchase orders, or informal arrangements. Document renewal rates by segment over the prior three years.
Validate all federal and state licensing, audit history, and chain-of-custody procedures to confirm no unresolved violations exist that could trigger buyer liability or disrupt operations post-close.
Review all DOT audit findings, SAMHSA-certified lab authorization letters, and collector qualification records. Confirm no active citations, consent orders, or pending regulatory investigations exist.
Verify all qualified collector certifications are current, transferable to a new owner, and compliant with 49 CFR Part 40 training requirements. Identify any expiring credentials.
Confirm state-level collection site permits, HIPAA compliance documentation, and any court-ordered testing program authorizations are active and assignable upon transaction close.
Evaluate lab and MRO vendor agreements, technology infrastructure, and owner dependency to determine transition risk and scalability potential for a roll-up or standalone acquisition strategy.
Examine SAMHSA-certified lab pricing schedules, exclusivity terms, and change-of-control provisions. Confirm MRO contractor agreements are assignable and margin is sustainable post-acquisition.
Identify whether the seller performs MRO reviews, manages key employer accounts personally, or holds certifications not held by any other staff member. Structure earnout and transition accordingly.
Assess LIMS platform, electronic chain-of-custody software, and HR or payroll system integrations. Identify paper-based workflows as operational liabilities requiring capital investment post-close.
Verify the Drug Testing Services acquisition qualifies for SBA financing, the purchase price is supportable by the verified cash flow, and the deal structure protects the buyer's downside.
Confirm the Drug Testing Services meets SBA 7(a) eligibility requirements: the business is for-profit, U.S.-based, within SBA size standards, and the buyer meets personal financial requirements. Some industries have specific SBA restrictions — verify before LOI.
Model verified normalized EBITDA against projected SBA loan payments at current rates. A $1M SBA 7(a) loan at 10.5% over 10 years costs approximately $13,000/month. The Drug Testing Services must generate at least 1.25x debt service coverage after a market-rate manager salary to pass underwriting.
Confirm the seller note is properly subordinated to the SBA loan and goes on 24-month standby as required by SBA rules. If an earnout is included, define exact measurement metrics, time period, and dispute resolution process before signing the purchase agreement.
Before signing a Letter of Intent, request these documents from the seller. Missing or incomplete items are a red flag — not a reason to proceed without them.
Valuation typically applies a 3.5x–6x EBITDA multiple to adjusted earnings that exclude pass-through lab charges. Businesses with DOT consortiums, MRO services, and diversified employer contracts command the higher end of the range.
Revenue concentration is the top concern. If one or two employer accounts represent more than 20% of collections volume, buyers face material churn risk post-close and should negotiate escrow holdbacks or retention-based earnouts.
Yes. SBA 7(a) financing is commonly used for drug testing acquisitions, typically requiring 10–15% buyer equity and a seller note of 5–10%. Clean regulatory history and recurring employer contracts support strong loan approval outcomes.
Legalization reduces employer willingness to test for cannabis in non-DOT segments, compressing discretionary testing volumes. Buyers should prioritize businesses with strong DOT-regulated client bases, where cannabis testing remains federally mandated.
More Drug Testing Services Guides
DealFlow OS surfaces targets with seller signals and motivation scores — so you know before you start diligence. Free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers